Highly containment laboratory in the National Institute of Infectious Diseases, Tokyo, Japan: activities, circumstances, and future challenges Masayuki.

Slides:



Advertisements
Similar presentations
Regional Centers of Excellence Academic defense against bioterrorism.
Advertisements

Any of the following risk factors within 3 weeks (21 days) before onset of symptoms 1,2 : Contact with blood or other body fluids of a patient known to.
Any of the following risk factors within 3 weeks (21 days) before onset of symptoms 1,2 : Contact with blood or other body fluids of a patient known to.
INDONESIA PREPAREDNESS AND RESPONSE ON EBOLA VIRUS DISEASE Coordination Meeting, 13 November 2014 dr. Wiendra Waworuntu, M.Kes Director of Surveillance,
Public health assessment Avian flu A(H5N1) situation Feb 9, 2004.
SPECIMEN HANDLING: from patient bedside to the laboratories (clinical, commercial and public health) Patricia A. Somsel, Dr.P.H. Michigan Department of.
Crimean Congo Hemorrhagic Fever- Pakistan Perspective National Institute of Health, Islamabad-Pakistan.
1 Antivirals in the Draft CDC Pandemic Plan David K. Shay Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.
CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Epidemiology Investigation for Ebola Virus Disease Lei Zhou, MD, Epidemiologist Public Health Emergency.
Preparedness for the detection of emerging-and re-emerging pathogens in Croatia Alemka Markotić, MD, PhD Associate professor University Hospital for Infectious.
VIRAL AND ZOONOTIC DISEASE RESEARCH PROGRM VZDRP Study. Monitor. Detect Empowering nations and agencies through collaboration, with the means to better.
Hepatitis web study H EPATITIS W EB S TUDY Hepatitis A: Epidemiology Presentation Prepared by: David Spach, MD and Nina Kim, MD Last Updated: May 31, 2011.
Principles and Practices of Biosafety Environmental Health and Safety San Diego State University.
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
1 Module 5 Supplemental Information Laboratory Diagnostics, Specimen Collection, and Biosafety Issues.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
U.S. Department of Defense Drug and Vaccine Development
What will be studied? What are the risks? September 10, 2007 National Emerging Infectious Diseases Laboratories.
Marburgviruses and Ebolaviruses – History, Fiction, and the Facts MIT Faculty Dinner Series on Biosecurity September 29, 2005 Jens H. Kuhn.
New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research.
What will be studied? What are the risks? Part II October 1, 2007 National Emerging Infectious Diseases Laboratories.
Ebola Virus Disease Dr. Oluwafemi Akinyele Popoola Lecturer and Consultant Community Physician Lecture delivered at Bodija-Ashi Baptist Church 14 th September,
Bioterrorism MLAB 2434: Microiology Keri Brophy-Martinez.
Biosafety and the Southeast Asian Clinical Infectious Diseases Network (SEAICRN) Rogier van Doorn Clinical Microbiologist Wellcome Trust Major Overseas.
Prevention and improved treatment of communicable diseases (HIV/AIDS and TB), including increasing preparedness for bioterrorism and epidemics Anneli Taal,
African Science Academy Development Initiative
The Global Threat of Infectious Diseases Background 20 th Century Re-Emergence of Infectious Diseases - Newly recognized diseases - Known diseases -
US biosafety experiences during the last two decades: Lessons and achievements PETER PALESE MOUNT SINAI SCHOOL OF MEDICINE, New York BIOSECURITY, ISTANBUL,
Ebola Virus Disease Clinical manifestations Ebola Virus Disease Clinical manifestations N. Shindo Lead, Clinical & Infection Control Pandemic & Epidemic.
National Institute of Health Pathom Sawanpanyalert, MD, DrPH National Institute of Health Department of Medical Sciences Ministry of Public Health, Thailand.
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
Local Emergency Response to Biohazardous Incidents Dr. Elizabeth Whalen, MD Medical Director Albany County Health Department April 8, 2005 Northeast Biological.
Emerging Infections in the United States Preparing for Ebola Maine EMS Prepared September 2014 Based on the CDC’s “Interim Guidance for Emergency Medical.
SARS Research Resources at NIAID Linda C. Lambert, Ph.D. Program Officer Influenza, SARS, and Related Viral Respiratory Diseases NIAID/NIH/DHHS.
1 WHO Communicable Diseases, Surveillance & Response SARS Diagnostics and Laboratory Needs: the WHO Perspective C.E. Roth Dangerous and New Pathogens Global.
Biosafety/ Biosecurity in Georgia Lela Bakanidze, Ph.D. National Center for Disease Control and Medical Statistics of Georgia Scientific Networking and.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Protecting American Agriculture 1 Avian Influenza: Agricultural Perspectives & Interventions March 2006.
Emerging Infectious Diseases: SARS and Avian Influenza Sonja J. Olsen, PhD International Emerging Infections Program Thailand Ministry of Public Health.
Ebola Virus Disease (EVD). Marburg and Ebola Virus Hemorrhagic Fevers Filovirus RNA virus Threadlike, filamentous morphology Viral epidemics from Africa.
World Health Organization, Regional Office for The Western Pacific Regional Activities Report and Preparation for the Upcoming Influenza Seasons THE 3rd.
As per CDC and WHO, Recent outbreak of Ebola Virus Disease(EVD), New cases and deaths attributable to EVD continue to be reported by the Ministries of.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
Central Asia Regional Health Security Workshop George C. Marshall European Center for Security Studies April 2012, Garmisch-Partenkirchen, Germany.
Influenza Nancy V. Rodway MD MPH MS Medical Director LakeHealth System Occupational Medicine and Urgent Care.
Communicable Disease Surveillance and Response, WHO Avian Influenza Credit: WHO Viet Nam.
Mr. C’s Joke/Riddle of the Day. The Role Canada is Playing How the World Keeps Diseases from Spreading Pt.2.
SAS-Coronavirus: Diagnosis, Antibody Responses and Biosafty Conserns Cheng Cao Beijing Institute of Biotechnology, China.
WHO / World Bank videoconference 19 September 2008
Wrap-up Day 2. Plenary Four: Pandemic and avian influenza updates Pandemic H1N1 – Origin of pandemic H1N1 virus – Genetically and antigenically homogenous.
Centers for Disease Control and Prevention (CDC): Fighting Diseases Worldwide Presented by: Angela Permon Resident Scientist Snook ISD Presented by: Angela.
“28,424 cases of Ebola and still counting—what have we learned
Emoryhealthcare.org One Year Later: Lessons Learned from Ebola in the U.S. and Academic Medicine’s Role in Preparing for the Next Threat Bryce Gartland,
RESULTS Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for disease control, Osong, Korea BACKGROUND.
Outline of Current Situation Survey on HIV/AIDS (Proposal) Ms. Keiko Dozono Director for AIDS and Emerging Infectious Disease Control Health and Safety.
Ebola SITREP and Response—2014 Matt Richardson, DrPH, MPH Health Director Denton County Health Department Jody Gonzalez Chief Denton County Emergency Services.
روش استاندارد انتقال نمونه هاي عفوني براساس الزامات بين المللي.
SARS Severe Acute Respiratory Syndrome Jeffrey S. Duchin, M.D. Chief, Communicable Disease Control, Epidemiology and Immunization Section, Public Health.
Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.
Ebola virus. Introduction Filoviridae Ebola, Marburg viruses Nonsegmented, negative-sense, single-stranded RNA viruses Viral hemorrhagic fever or Ebola.
Crimean-Congo Fever- A Serious Threat For Public Health
3rd September 2010 INSERM, Lyon
Bioterrorism: A Changing World and What You Can Do
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Hospital Clinic – University of Barcelona
Avian Influenza Prevention and Control from an OIE Perspective
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Presentation transcript:

Highly containment laboratory in the National Institute of Infectious Diseases, Tokyo, Japan: activities, circumstances, and future challenges Masayuki Saijo, M.D., Ph. D Department of Virology 1, National Institute of Infectious Diseases

Current situation of BSL-4 facilities in NIID Glove box-type BSL-4 facility was constructed and installed in the NIID (Murayama annex) in early 1980’s. Role of the Special Pathogens Laboratory in Dept Virol 1, NIID –Basic science for viral hemorrhagic fevers and other emerging virus infections –Quality Control of Smallpox vaccine –Preparedness for the risk of viral The BSL-4 facility has not yet operated as BSL-4 facility but as BSL- 3 laboratories. –Opposition by the residents and local municipality to the operation of the facility as BSL-4

Japanese Infectious Control Law Ebolavirus, Marburg virus, Crimean-Congo hemorrhagic fever virus, Lassa virus, South American hemorrhagic fever viruses, Variola virus, and Yersinia pestis are defined as BSL-4 pathogens in the JIDC law. The law restricts importation, possession, transportation, transfer and sterilization. Furthermore, the law tightened the control of animal importation.

Research Activities in Highly Containment Laboratory Development of diagnostic systems for Hemorrhagic fever viruses (Ebola, Marburg, CCHF, Lassa, etc) -mission Monkeypox virus infections –Pathogenesis, diagnostics, immunology SARS –Diagnostics, Vaccine development, Animal model development, and Pathogenesis Efficacy assessment of a newly developed highly pathogenic avian influenza vaccine using nonhuman primate models Efficacy assessment of a highly attenuated smallpox vaccine, LC16m8, using nonhuman primate models –Induction of protective efficacy, Post-exposure vaccination, long-term efficacy

Recombinant NP-based diagnosis of CCHF Tang Q, et al. A patient with Crimean-Congo hemorrhagic fever diagnosed with recombinant nucleoprotein-based antibody detection systems. Clin Diag Lab Immunol 10: , 2003

Clinical course Patient: 28-year old shepherd in the Xinjiang Uygur Autonomous Region in 2001 Symptoms : fever, unconsciousness, hemorrhage (nostril, gingiva, rectum) Laboratory findings : anemia (Hb 10.0 g/dl), thrombocytopenia (8.4  /L), elevated transaminases (ALT, AST, LDH;173, 216, 268 U/L), hyperbilirubinamia, hypoalbuminamia

Virological test results on CCHF virus infection Days from onset 159 (Days) RT-PCR (nested)+-- Ag-capture ELISA (OD 405 ) IgG-ELISA (1:100) (OD 405 ) (1:400) IgM-capture ELISA (OD 405 ) (1:100) (1:400) NC

International collaborations US CDC (Atlanta, GA) –Ebola, Marburg, Smallpox (vaccine study) INSERM (Lyon, France) –Lassa, Marburg China CDC (Beijing, China) –Crimean-Congo hemorrhagic fever RITM (Manila, the Philippines) –Reston Ebolavirus University of Maiduguri (Maiduguri, Nigeria) –Hemorrhagic fevers University of Ghana (Acura, Ghana) –Hemorrhagic fevers

Future challenges -key player- Need to operate the facility as BSL-4 laboratory in order to prepare the possible outbreak of highly pathogenic hemorrhagic fever virus infections and other novel emerging infections not only in Japan, but also in the other part of the world. Need to play an important role to combat the highly pathogenic infections in collaboration with the key partners in the world.

Future challenges -operation- Requirement of mutual understandings on the safety and operation risks between the NIID and communities. Requirement of mutual collaboration to the operation of BSL-4 facilities between NIID and the Ministry of Health, Labor, and Welfare of Japan.

Action plans Mutual understanding –Periodical seminars on infections diseases to the residents in communities –Establishment of Safety committee between the local municipalities and the NIID –Others Mutual collaboration –Between the NIID and MHLW –Between the NIID and Ministry of Education, Culture, Science, and Technology –Between the NIID and Academics